Weekly Vaccination with Copaxone as a Potential Therapy for Dry Age Related Macular Degeneration
This study is currently recruiting participants.
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give Copaxone subcutaneous injections to adults with dry age related macular degeneration (Dry AMD).
Ages Eligible for Study: 50 years old and older
Genders Eligible for Study: Both
Dr. Richard Rosen, Retina Vitreous Specialist
Katy Tai, Research Manager
email@example.com or 212-979-4251
Home > Current Research > Clinical Trials in Ophthalmology > Copaxone Dry AMD Therapy Trial